08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

CPP-115: Phase Ib data

Top-line data from a 2-part, U.S. Phase Ib trial in healthy volunteers showed that CPP-115 for 14 days increased GABA levels by 150-200% from baseline in both the parietal-occipital cortex and the supplementary motor area...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Vigabatrin: Phase I/II data

Top-line data from an open-label, U.S. Phase I/II trial in 4 Tourrette’s disorder patients who were refractory to all other previous treatments showed that 1 patient receiving twice-daily oral vigabatrin for 8 weeks achieved a...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

CPP-115: Phase I started

Catalyst began a 2-part, U.S. Phase Ib trial to evaluate single and multiple doses of CPP-115 in up to 38 healthy, male volunteers. The trial will evaluate increases in brain GABA levels, which Catalyst believes...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Catalyst Pharma neurology news

Catalyst disclosed in its 4Q12 earnings that it will require a strategic partner or grant funding for the "near-term advancement" of GABA transaminase inhibitor CPP-115 to treat West syndrome (infantile spasms). Last year,...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Sabril vigabatrin neurology data

Lundbeck reported 3-year data from its registry of 4,292 patients with refractory complex partial seizures and infantile spasms receiving Sabril. Specifically, 2,339 (55%) patients discontinued Sabril treatment, of which 14 (0.6%) discontinued due to visual...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Vigabatrin: Phase IIb data

Top-line data from the double-blind, U.S. Phase IIb CPP-01005 trial in 207 cocaine addicts showed that CPP-109 missed the primary endpoint of a greater proportion of cocaine-free patients during the last 2 weeks of treatment...
01:41 , Nov 9, 2012 |  BC Extra  |  Clinical News

Catalyst falls on CPP-109 Phase IIb miss

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) fell $0.95 (66%) to $0.50 on Thursday after the company reported that CPP-109 missed the primary endpoint of a greater proportion of cocaine-free patients during the last two weeks of...
07:00 , Oct 1, 2012 |  BC Week In Review  |  Clinical News

Vigabatrin: Phase II started

Catalyst said investigators at the Mount Sinai School of Medicine began an open-label, U.S. Phase I/II trial to evaluate oral CPP-109 twice daily for 8 weeks in about 10 young adults with treatment-refractory Tourette's disorder....
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Vigabatrin: Additional Phase II data

Additional data from the double-blind, U.S. Phase II CPP-01004 trial in 186 cocaine addicts showed that twice-daily 1.5 g vigabatrin for 12 weeks did not lead to visual acuity reductions or significant peripheral visual constriction...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

CPP-115: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in 55 healthy volunteers showed that single ascending-doses of 5-500 mg oral CPP-115 were well tolerated with no serious adverse events reported. Mean time to average peak blood...